US FTC approves Teva’s $40.5bn deal for Allergan’s generics business
The US Federal Trade Commission (FTC) has approved Teva Pharmaceutical Industries’ proposed $40.5bn acquisition of Allergan’s generics business.
The approval was granted after Teva agreed to divest more than 75 generic drugs to eleven companies.
The divested products will include anesthetics, antibiotics, weight loss drugs, oral contraceptives, and treatments for several diseases and conditions.
The agreement, which the FTC says will help to preserve competition in the US pharmaceutical market, is the largest-ever drug divestiture ordered by the regulator in a pharmaceutical merger case.
Click on this link for more information.